Tian Zhang, MD

Adjunct Associate Professor in the Department of Medicine
Campus mail DUMC 103861, Durham, NC 27710
Phone (919) 668-4667
Email address tian.zhang2@duke.edu

Education and Training

  • Fellowship in Hematology-Oncology, Medicine, Duke University School of Medicine, 2012 - 2015
  • Internal Medicine Residency, Medicine, Duke University School of Medicine, 2009 - 2012
  • M.H.S., Duke University School of Medicine, 2019
  • M.D., Harvard Medical School, 2009

Publications

Saidian, Ava, Kevin Hakimi, Justine Panian, Archana Ajmera, Pedro C. Barata, Stephanie A. Berg, Steven Lee Chang, et al. “Impact of neoadjuvant immune checkpoint inhibitor therapy on primary tumor size and complexity: Correlation with surgical quality and short term oncological outcomes.” In Journal of Clinical Oncology, 40:390–390. American Society of Clinical Oncology (ASCO), 2022. https://doi.org/10.1200/jco.2022.40.6_suppl.390.

Full Text

Dzimitrowicz, Hannah Elizabeth, Lauren E. Wilson, Bradford E. Jackson, Lisa Spees, Christopher Baggett, Melissa A. Greiner, Deborah Kaye, et al. “Factors associated with the quality of end-of-life care for patients with metastatic renal cell carcinoma.” In Journal of Clinical Oncology, 40:300–300. American Society of Clinical Oncology (ASCO), 2022. https://doi.org/10.1200/jco.2022.40.6_suppl.300.

Full Text

Panian, Justine, Ava Saidian, Kevin Hakimi, Archana Ajmera, Pedro C. Barata, Stephanie A. Berg, Steven Lee Chang, et al. “Pathologic outcomes at cytoreductive nephrectomy (CN) following immunotherapy (IO) for patients with advanced renal cell carcinoma (RCC).” In Journal of Clinical Oncology, 40:334–334. American Society of Clinical Oncology (ASCO), 2022. https://doi.org/10.1200/jco.2022.40.6_suppl.334.

Full Text

Schöffski, Patrick, Daniel S. W. Tan, Miguel Martín, María Ochoa-de-Olza, John Sarantopoulos, Richard D. Carvajal, Chrisann Kyi, et al. “Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies.” J Immunother Cancer 10, no. 2 (February 2022). https://doi.org/10.1136/jitc-2021-003776.

PMID
35217575
Full Text

Atiq, Saad, Nathan Hirshman, Afreen Shariff, and Tian Zhang. “The management of toxicities from immune, targeted and ADCs treatments in patients with urothelial cancer.” Urol Oncol, December 30, 2021. https://doi.org/10.1016/j.urolonc.2021.10.002.

PMID
34973855
Full Text

Bitting, Rhonda L., Patrick Healy, Daniel J. George, Monika Anand, Sung Kim, Tina Mayer, Carol Winters, et al. “Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial.” Eur Urol Oncol 4, no. 6 (December 2021): 948–54. https://doi.org/10.1016/j.euo.2020.01.005.

PMID
32063492
Full Text

Wheeler, Stephanie B., Lisa P. Spees, Bradford E. Jackson, Christopher D. Baggett, Lauren E. Wilson, Melissa A. Greiner, Deborah R. Kaye, et al. “Patterns and Predictors of Oral Anticancer Agent Use in Diverse Patients With Metastatic Renal Cell Carcinoma.” Jco Oncol Pract 17, no. 12 (December 2021): e1895–1904. https://doi.org/10.1200/OP.20.01082.

PMID
34138665
Full Text

Tucker, Matthew D., Landon C. Brown, Yu-Wei Chen, Chester Kao, Nathan Hirshman, Emily N. Kinsey, Kristin K. Ancell, et al. “Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma.” Biomark Res 9, no. 1 (November 3, 2021): 80. https://doi.org/10.1186/s40364-021-00334-4.

PMID
34732251
Full Text

Schmidt, Andrew L., Matthew D. Tucker, Ziad Bakouny, Chris Labaki, Chih-Yuan Hsu, Yu Shyr, Andrew J. Armstrong, et al. “Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19.” Jama Netw Open 4, no. 11 (November 1, 2021): e2134330. https://doi.org/10.1001/jamanetworkopen.2021.34330.

PMID
34767021
Full Text

Pages